<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596540</url>
  </required_header>
  <id_info>
    <org_study_id>SEL-212/302</org_study_id>
    <secondary_id>2020-003070-45</secondary_id>
    <nct_id>NCT04596540</nct_id>
  </id_info>
  <brief_title>A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II</brief_title>
  <acronym>DISSOLVE II</acronym>
  <official_title>A Randomized Double-Blind, Placebo-Controlled Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Selecta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Selecta Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm&#xD;
      trials to determine the safety and efficacy of two different dose levels of SEL-212 compared&#xD;
      to placebo. Approximately 105 patients, stratified as to the presence or absence of tophi,&#xD;
      will be randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with&#xD;
      one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each&#xD;
      trial (SEL-212/301 and SEL-212/302). Analysis of efficacy will be performed at Day 28 of&#xD;
      Treatment Period 6. Safety will be monitored throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is one of two replicate randomized, double-blind, placebo-controlled, parallel arm&#xD;
      trials to determine the safety and efficacy of two different dose levels of SEL-212 compared&#xD;
      to placebo. Approximately 105 patients, stratified as to the presence or absence of tophi,&#xD;
      will be randomized in a 1:1:1 allocation ratio prior to Baseline to receive treatment with&#xD;
      one of two dose levels of SEL-212 or placebo every 28 days for approximately 6 months in each&#xD;
      trial (SEL-212/301 and SEL-212/302). The SEL-212 doses will differ as to the SEL-110.36&#xD;
      component. Participants will receive SEL-037 administered at a dose of 0.2 mg/kg via&#xD;
      intravenous (IV) infusion immediately after receiving SEL-110.36 at a dose of either 0.1&#xD;
      mg/kg (SEL-212A) or 0.15 mg/kg (SEL-212B) via IV infusion. The placebo will consist of normal&#xD;
      saline.&#xD;
&#xD;
      Placebo subjects who complete the study will be offered enrollment in an open-label extension&#xD;
      study for treatment with SEL-212 (SEL-212/303).&#xD;
&#xD;
      Efficacy assessments will be conducted at intervals that are appropriate to determine&#xD;
      treatment effect with samples for the primary endpoint drawn during Treatment Period 6.&#xD;
      Safety will be monitored throughout the study with an independent data safety monitoring&#xD;
      board (DSMB).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum uric acid control during Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>The percentage of patients who achieve and maintain reduction in serum uric acid (sUA) &lt; 6mg/dL for at least 80% of the time during month 6 in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tender and Swollen Joint Counts</measure>
    <time_frame>6 months</time_frame>
    <description>To assess changes in number of tender and swollen joints in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tophus burden</measure>
    <time_frame>6 months</time_frame>
    <description>To assess change in tophus burden by photographic area assessments in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAQ-DI</measure>
    <time_frame>6 months</time_frame>
    <description>To assess change in Patient Reported Outcomes (PROs) including assessments of activity limitation (HAQ-DI) in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>6 months</time_frame>
    <description>To assess change in Patient Reported Outcomes (PROs) including assessments of patients' quality of life (QoL) (SF-36) in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gout flare Incidence</measure>
    <time_frame>6 months</time_frame>
    <description>To assess changes in gout flare incidence in patients with gout refractory to conventional treatment treated with two different dose levels of SEL-212 compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Chronic Gout</condition>
  <arm_group>
    <arm_group_label>SEL-212A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of SEL-212A every 28 days for a total of up to 12 infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL-212B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of SEL-212B every 28 days for a total of up to 12 infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV infusion of Normal Saline every 28 days for a total of up to 12 infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL-212A</intervention_name>
    <description>SEL-212A Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase&#xD;
Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR</description>
    <arm_group_label>SEL-212A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL-212B</intervention_name>
    <description>SEL-212B Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase&#xD;
Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR</description>
    <arm_group_label>SEL-212B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has negative results of an FDA Emergency Use Authorized COVID-19 molecular assay for&#xD;
             detection of SARS-CoV-2 RNA from a respiratory specimen;&#xD;
&#xD;
          2. History of symptomatic gout defined as:&#xD;
&#xD;
               1. ≥ 3 gout flares within 18 months of Screening or&#xD;
&#xD;
               2. Presence of ≥ 1 gout tophus or&#xD;
&#xD;
               3. Current diagnosis of gouty arthritis&#xD;
&#xD;
          3. At the Screening Visit: male age 21 - 80 years, inclusive, or female of&#xD;
             non-childbearing potential age 21-80 years, inclusive, where nonchildbearing potential&#xD;
             is defined as:&#xD;
&#xD;
               1. &gt; 6 weeks after hysterectomy with or without surgical bilateral&#xD;
                  salpingo-oophorectomy or&#xD;
&#xD;
               2. Post-menopausal (&gt; 24 months of natural amenorrhea or in the absence of &gt;24&#xD;
                  months of amenorrhea, one documented confirmatory FSH measurement)&#xD;
&#xD;
          4. Has chronic refractory gout defined as having failed to normalize sUA and whose signs&#xD;
             and symptoms are inadequately controlled with any of the xanthine oxidase inhibitors,&#xD;
             or for whom these drugs are contraindicated for the patient;&#xD;
&#xD;
          5. Has at the Screening Visit SUA ≥ 7 mg/dL&#xD;
&#xD;
          6. Negative serology for HIV-1/-2 and negative antigen to hepatitis B and negative&#xD;
             antibodies to hepatitis C;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history of anaphylaxis, severe allergic reactions, or severe atopy;&#xD;
&#xD;
          2. Has a history of any allergy to pegylated products, including, but not limited to&#xD;
             pegloticase (Krystexxa®), peginterferon alfa-2a (Pegasys®), peginterferon alfa-2b&#xD;
             (PegIntron®), pegfilgrastim (Neulasta®), pegaptanib (Macugen®), pegaspargase&#xD;
             (Oncaspar®), pegademase (Adagen®), peg-epoetin beta (Mircera®), pegvisomant&#xD;
             (Somavert®) certolizumab pegol (Cimzia®), naloxegol (Movantik®), peginesatide&#xD;
             (Omontys®), and doxorubicin liposome (Doxil®);&#xD;
&#xD;
          3. Is taking and cannot discontinue known major CYP3A4/P-gp inhibitors or major&#xD;
             CYP3A4/P-gp inducers at least 14 days before dosing. Patients must remain off these&#xD;
             medications for the duration of the study, including natural products such as St.&#xD;
             John's Wort or grapefruit juice.&#xD;
&#xD;
          4. Is taking drugs known to interact with rapamycin (sirolimus - Rapamune®) such as&#xD;
             cyclosporine, diltiazem, erythromycin, ketoconazole, posaconazole, voriconazole,&#xD;
             itraconazole, rifampin, verapamil unless they are stopped 14 days prior to dosing and&#xD;
             will not be used/prescribed during the trial.&#xD;
&#xD;
          5. Is a post-menopausal woman that has initiated or had a change in dose of hormone&#xD;
             replacement therapy (HRT) less than 1 month prior to the Screening Visit or during the&#xD;
             Screening Phase.&#xD;
&#xD;
          6. Had a gout flare during Screening that was resolved for less than 1 week prior to&#xD;
             first treatment with study drug (exclusive of chronic synovitis/arthritis) unless the&#xD;
             patient has a history of inter-flare intervals of &lt; 1 week.&#xD;
&#xD;
          7. Has uncontrolled diabetes at Screening with HbA1c ≥ 8.5%;&#xD;
&#xD;
          8. Has fasting Screening glucose &gt; 240 mg/dL;&#xD;
&#xD;
          9. Has fasting Screening triglyceride &gt; 500 mg/dL;&#xD;
&#xD;
         10. Has fasting Screening low-density lipoprotein (LDL) &gt; 200 mg/dL;&#xD;
&#xD;
         11. Has glucose-6-phosphate dehydrogenase (G6PD) deficiency;&#xD;
&#xD;
         12. Has uncontrolled hypertension defined as blood pressure &gt; 170/100 mmHg at Screening&#xD;
             and 1 week prior to dosing&#xD;
&#xD;
         13. Individual laboratory values which are exclusionary&#xD;
&#xD;
               -  White blood cell count (WBC) &lt; 3.0 x109/L&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) or alanine amino transferase (ALT) &gt; 3x&#xD;
                  upper limit of normal (ULN) in the absence of known active liver disease&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73 m2&#xD;
&#xD;
               -  Urine albumin creatinine ratio (UACR) &gt; 3.0&#xD;
&#xD;
               -  Hemoglobin (Hgb) &lt; 9 g/dL&#xD;
&#xD;
               -  Serum phosphate &lt; 2.0 mg/dL&#xD;
&#xD;
         14. Is receiving ongoing treatment for arrhythmia, including placement of an implantable&#xD;
             defibrillator, unless considered stable and on active treatment;&#xD;
&#xD;
         15. Has evidence of unstable cardiovascular disease or unstable cerebrovascular vascular&#xD;
             disease. This includes patients who have had a cardiac/vascular event(s) in the last 3&#xD;
             months including heart attack, stroke or vascular bypass surgery or patients who are&#xD;
             deemed, by their physician or PI, to have active cardiovascular, cerebrovascular or&#xD;
             peripheral vascular symptoms/disease inadequately controlled by medication;&#xD;
&#xD;
         16. Has congestive heart failure, New York Heart Association Class III or IV;&#xD;
&#xD;
         17. Unless clinically stable and/or appropriately treated, electrocardiogram (ECG) with&#xD;
             evidence of clinically significant arrhythmia or other abnormalities that, in the&#xD;
             opinion of the investigator, are consistent with significant underlying cardiac&#xD;
             disease;&#xD;
&#xD;
         18. History of significant hematological disorders within 5 years or autoimmune disorders,&#xD;
             and/or patient is currently immunosuppressed or immunocompromised;&#xD;
&#xD;
         19. Prior exposure to any experimental or marketed uricase (e.g., rasburicase (Elitek,&#xD;
             Fasturtec), pegloticase (Krystexxa®®), pegadricase (SEL 037))&#xD;
&#xD;
         20. Patient has received a live vaccine in the previous 6 months.&#xD;
&#xD;
         21. Patient is planning to receive any live vaccine during the study.&#xD;
&#xD;
         22. History of malignancy within the last 5 years other than basal skin cancer;&#xD;
&#xD;
         23. Patients with a documented history of moderate or severe alcohol or substance use&#xD;
             disorder within the 12 months prior to randomization.&#xD;
&#xD;
         24. History of or evidence of clinically severe interstitial lung disease&#xD;
&#xD;
         25. Immunocompromised state, regardless of etiology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female of non-childbearing potential defined as either &gt;6 weeks after hysterectomy with or without surgical bilateral salpingo-oophorectomy OR post-menopausal (&gt; 24 months of natural amenorrhea or in the absence of &gt; 24 months of amenorrhea, one documented confirmatory FSH measurement)</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter G. Traber, MD</last_name>
    <phone>617-923-1400</phone>
    <email>ptraber@selectabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>D&amp;H National Research Centers</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grether Rodriguez</last_name>
      <phone>786-375-6210</phone>
      <email>grdgz@nationalresearchcenters.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Napa Research</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jhonny Bonilla</last_name>
      <phone>954-773-9889</phone>
      <email>jbonilla@napatrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of North Georgia, LLC</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Corn</last_name>
      <phone>678-677-8824</phone>
      <email>lcorn@articularishealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Injury Care Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Venard</last_name>
      <phone>208-939-2100</phone>
      <email>bridget@injurycareresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials at Ravenswood Rheumatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zander Schrempp</last_name>
      <phone>773-275-3500</phone>
      <email>zschrempp@greatlakesclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Miedema</last_name>
      <phone>773-275-3500</phone>
      <email>jmiedema@greatlakesclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Lormore</last_name>
      <phone>301-942-6610</phone>
      <email>mlormore@arapc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Triad Clinical Trials</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shavonna Haamid</last_name>
      <phone>336-235-0991</phone>
      <email>s.haamid@triad.twcbc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Claycomb</last_name>
      <phone>814-693-0300</phone>
      <phone_ext>124</phone_ext>
      <email>altoonaresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amarillo Center for Clinical Research, Ltd.</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Mizer</last_name>
      <phone>806-352-2453</phone>
      <email>cmizer@allergyarts.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heritage Rheumatology and Arthritis Care</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chudi Nwoye</last_name>
      <phone>972-299-8399</phone>
      <email>chudinwoye@pccrsolutions.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, PLLC - Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seinna Gray</last_name>
      <phone>509-838-6500</phone>
      <phone_ext>320</phone_ext>
      <email>sgray@arthritisnw.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LTD Israeli-Georgian Medical Research Clinic &quot;Helsicore&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketevan Gabunia, MD</last_name>
      <phone>995 599 577 977</phone>
      <email>keti.gab23@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JSC &quot;Evex Hospitals&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Tskhovrebashvili, MD</last_name>
      <phone>+995599147085</phone>
      <email>ninatskhovreba@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LTD MediClub Georgia</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gochitashvili</last_name>
      <phone>+995599510806</phone>
      <email>d.gochitashvili@mcg.ge</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LTD &quot;The First Medical Center&quot;</name>
      <address>
        <city>Tbilisi</city>
        <zip>0180</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Besik Tsintsadze</last_name>
      <phone>+995 558 100 725</phone>
      <email>b.tsintsadze95@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

